This is a press release by Kiadis Pharma N.V.
(“Kiadis”) in connection with the public offer by
Sanofi Foreign Participations B.V. (“the
Offeror”), a wholly owned subsidiary of Sanofi
(“Sanofi”), for all the issued and outstanding
ordinary shares in the capital of Kiadis launched on February 12,
2021 (the “Offer”). This announcement does not
constitute an offer, or any solicitation of any offer, to buy or
subscribe for any securities. Any offer will be made only by means
of the offer memorandum approved by the Dutch Authority for the
Financial Markets (Autoriteit Financiële Markten) on February 10,
2021 and recognized by the Belgian Authority for the Financial
Markets (Autoriteit voor Financiële Diensten en Markten) on
February 11, 2021 (the “Offer Memorandum”). This
announcement is not for release, publication or distribution, in
whole or in part, in or into, directly or indirectly, any
jurisdiction in which such release, publication or distribution
would be unlawful. Capitalized terms used but not defined in this
press release will have the meaning given thereto in the Offer
Memorandum.
Kiadis EGM adopts all resolutions related
to the recommended public offer by
Sanofi
Amsterdam, The Netherlands, March 30,
2021 – Kiadis Pharma N.V. (“Kiadis” or the “Company”)
(Euronext Amsterdam and Brussels: KDS) announces
that all resolutions related to the recommended public offer by
Sanofi have been adopted at the extraordinary general meeting of
shareholders (the “EGM”) held today.
Arthur Lahr, CEO of Kiadis,
commented: “The adoption of all resolutions at today’s EGM
is an important next step in the Offer process, both for Kiadis and
Sanofi. The minimum acceptance level threshold has now been lowered
to 80%. While the Acceptance Period continues until April 12, 2021,
Kiadis and Sanofi will continue to work constructively together to
satisfy the remaining Offer conditions.”
The following resolutions were all adopted at
the EGM:
- Conditional amendment of the articles of association of Kiadis
(following Settlement);
- Conditional amendment of the articles of association of Kiadis
(following delisting);
- Conditional appointment of Mr. Frank Nestle, Mr. Kripa Ram and
Mr. Jérémie Girard as new members of the Kiadis Supervisory Board
as of Settlement;
- Re-appointment of Mr. Arthur Lahr as a member of the Kiadis
Management Board;
- Conditional appointment of Ms. Marion Zerlin as a member of the
Kiadis Management Board as of Settlement;
- Discharge of each member of the Kiadis Management Board and the
Kiadis Supervisory Board;
- Conditional full and final discharge of Messrs. Martijn
Kleijwegt, Berndt Modig, Otto Schwarz and Subhanu Saxena, members
of the Kiadis Supervisory Board; and
- The Post-Offering Restructuring, being (i) the approval of the
resolution of the Kiadis Management Board to pursue the Asset Sale
and (ii) subject to completion of the Asset Sale, to dissolve
Kiadis, (iii) the appointment of Stichting Liquidator Kiadis as the
liquidator of Kiadis, (iv) the approval of the reimbursement of the
liquidator’s reasonable salary and costs and (v) the appointment of
Sanofi S.A. as the custodian of Kiadis’ books and records following
its dissolution.
Because the Post-Offer Restructuring Resolution
has been adopted, the minimum acceptance level threshold has been
lowered from 95% to 80%. Reference is made to Section 6.6(a)(i) of
the Offer Memorandum.
Kiadis and the Offeror continue to work
constructively to satisfy the other Offer Conditions and are making
timely progress, anticipating that the Acceptance Period shall
close on April 12, 2021. Please see the Offer Memorandum for
information on how Shareholders can tender their Shares under the
Offer.
Dutch Translation/Nederlandse
vertaling
Kiadis Pharma N.V. (“Kiadis” of de
“Vennootschap”) (Euronext Amsterdam en Brussel:
KDS) kondigt aan dat alle besluiten met betrekking tot het
voorgenomen openbare bod door Sanofi zijn aangenomen door de
buitengewone aandeelhoudersvergadering (de “BAVA”)
die vandaag plaatsvond.
Arthur Lahr, CEO van Kiadis,
zegt, “De goedkeuring van alle besluiten op de BAVA van
vandaag is een belangrijke stap in het biedingsproces, voor zowel
Kiadis als Sanofi. Het minimale acceptatieniveau is nu verlaagd tot
80%. Tijdens de Aanmeldingstermijn, die doorloopt tot 12 april
2021, zullen Kiadis en Sanofi constructief blijven samenwerken om
de resterende Biedingsvoorwaarden te vervullen.”
De volgende besluiten zijn allemaal aangenomen
op de BAVA:
- Voorwaardelijke wijziging van de statuten van Kiadis (na de
Overdracht);
- Voorwaardelijke wijziging van de statuten van Kiadis (na de
beëindiging van de beursnotering);
- Voorwaardelijke benoeming van dhr. Frank Nestle, dhr. Kripa Ram
en dhr. Jérémie Girard als nieuwe leden van de Raad van
Commissarissen van Kiadis vanaf de Overdracht;
- Herbenoeming van dhr. Arthur Lahr als lid van de Raad van
Bestuur van Kiadis;
- Voorwaardelijke benoeming van mevr. Marion Zerlin als lid van
de Raad van Bestuur van Kiadis vanaf de Overdracht;
- Verlening van decharge aan ieder lid van de Raad van Bestuur en
de Raad van Commissarissen van Kiadis;
- Voorwaardelijke volledige en finale kwijting van de heren
Martijn Kleijwegt, Berndt Modig, Otto Schwarz en Subhanu Saxena,
leden van de Raad van Commissarissen van Kiadis; en
- De Herstructurering na de Aanbieding, zijnde (i) de goedkeuring
van het besluit van de Raad van Bestuur van Kiadis om de Verkoop
van Activa voort te zetten en, (ii) onder voorbehoud van voltooiing
van de Verkoop van Activa, om Kiadis te ontbinden, (iii) de
benoeming van Stichting Liquidator Kiadis als de vereffenaar van
Kiadis, (iv) de goedkeuring van de vergoeding van het redelijke
salaris en de kosten van de vereffenaar en (v) de aanstelling van
Sanofi S.A. als de bewaarder van de boeken en bescheiden van Kiadis
na haar ontbinding.
Omdat het besluit tot de Herstructurering na de
Aanbieding is aangenomen, is het minimale acceptatieniveau verlaagd
van 95% tot 80%. Verwezen wordt naar Sectie 6.6(a)(i) van het
Biedingsbericht.
Kiadis en de Bieder blijven constructief
samenwerken om de andere Biedingsvoorwaarden te vervullen en boeken
goede vooruitgang, in de verwachting dat de Aanmeldingstermijn zal
sluiten op 12 april 2021. Zie het Biedingsbericht voor informatie
over hoe Aandeelhouders hun Aandelen onder het Bod kunnen
aanbieden.
Dit is een samenvatting van het
Engelstalige persbericht. Bij eventuele verschillen is de tekst van
het Engelstalige persbericht altijd leidend.
Documentation The agenda for
the EGM, the explanatory notes and accompanying documents and the
voting results of the EGM are available on Kiadis’ website:
www.kiadis.com under “For Investors – Shareholder Meetings”.
Further Information This
announcement contains select, condensed information regarding the
Offer and does not replace the Offer Memorandum and/or the Position
Statement. The information in this announcement is not complete and
additional information is contained in the Offer Memorandum and the
Position Statement.
Digital copies of the Offer Memorandum are
available on the website of the Offeror (www.sanofi.com) and
digital copies of the Position Statement are available on the
website of Kiadis (www.kiadis.com). Such websites do not constitute
part of, and are not incorporated by reference into, the Offer
Memorandum. Copies of the Offer Memorandum and the Position
Statement are on request also available free of charge at the
offices of Kiadis and the Settlement Agent at the addresses
below:
Kiadis Kiadis Pharma N.V.Paasheuvelweg 25A1105 BP AmsterdamThe
Netherlands |
Settlement AgentING Bank N.V.Bijlmerdreef 106 1102 CT Amsterdam The
Netherlands |
For more information:
Kiadis: Maryann
Cimino, Director, Corporate Affairs Tel: +1 (617) 710-7305
m.cimino@kiadis.com |
Kiadis Media Relations ContactsLifeSpring
Life Sciences Communication: Leon Melens (Amsterdam) Tel:
+31 6 538 16 427 lmelens@lifespring.nl Optimum Strategic
Communications: Mary Clark, Supriya Mathur Tel: +44 203
950 9144 kiadis@optimumcomms.com |
About Kiadis Founded in 1997,
Kiadis is committed to developing innovative cell-based medicines
for patients with life-threatening diseases. With headquarters in
Amsterdam, The Netherlands, and offices and activities across the
United States, Kiadis is reimagining medicine by leveraging the
natural strengths of humanity and our collective immune system to
source the best cells for life.
Kiadis is listed on the regulated market of
Euronext Amsterdam and Euronext Brussels since July 2, 2015, under
the symbol KDS. Learn more at www.kiadis.com.
Disclaimer The information in
the press release is not intended to be complete. This announcement
is for information purposes only and does not constitute an offer,
or any solicitation of any offer, to buy or subscribe for any
securities.
The distribution of this press release may, in
some countries, be restricted by law or regulation. Accordingly,
persons who come into possession of this document should inform
themselves of and observe these restrictions. To the fullest extent
permitted by applicable law, Kiadis disclaims any responsibility or
liability for the violation of any such restrictions by any person.
Any failure to comply with these restrictions may constitute a
violation of the securities laws of that jurisdiction. Neither
Kiadis, nor any of its advisors assumes any responsibility for any
violation by any of these restrictions. Any Kiadis shareholder who
is in any doubt as to his or her position should consult an
appropriate professional advisor without delay.